

the current technological barriers and ultimately enables the cataloging of the expression levels of all genes in a cell type. The culmination of this CRADA could provide a means to simultaneously screen the mRNA variations in a multitude of cell types or provide a means for the genomic fingerprinting of cellular DNA.

Role of NINDS

1. The LNP will provide its expertise in the quantitative reverse transcription polymerase chain reaction (RT-PCR) protocol it developed as well as a custom library of primers for over 100 different genes.

2. Collaborate in designing instrumentation adapted for high volume, high resolution gene expression analysis.

3. Collaborate in the formulation, evaluation, optimization of experimental protocols based on the quantitative RT-PCR protocols identified above.

The role and criteria for selection of the successful company(ies) under the CRADA will include, but may not be limited to, the following:

1. Having an established ability to design, manufacture or modify in one or more of the following: Thermocycling devices, capillary electrophoresis devices, automated detection systems (i.e. fluorescence or chromophoric) and laboratory robotics.

2. Ability to provide appropriate instrumentation either owned by the company or obtained through third party licensing agreements.

3. Ability to market and sell the final product produced through the collaboration.

Dated: June 16, 1995.

Barbara McGarey,

Deputy Director, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 95-16233 Filed 6-30-95; 8:45 am]

BILLING CODE 4140-01-P

Meeting of the Panel to Assess the NIH Investment in Research on Gene Therapy

Notice is hereby given that the Panel to Assess the NIH Investment in Research on Gene Therapy, a fact-finding group reporting to the Advisory Committee to the Director (ACD), National Institutes of Health (NIH), will convene two regional meetings to provide the Panel with an opportunity to hear presentations from researchers regarding activities relevant to gene therapy. The first meeting will be held at Building 31C, Conference Room 10, National Institutes of Health, Bethesda,

Maryland 20892, on July 13, 1995. The second meeting will be held at the Sir Francis Drake Hotel on Union Square, 450 Powell Street, San Francisco, California 94102, on August 17, 1995. These meetings will begin at approximately 9:30 a.m. and will end at approximately 5 p.m.

The goal of the Panel is to make recommendations to the ACD about the scientific areas that NIH should emphasize and the funding mechanisms that should be employed in order best to advance the development of gene therapy.

Written statements will be accepted and provided to the Panel prior to the meetings. Statements should be sent to Judith H. Greenberg, Ph.D., National Institutes of Health, Natcher Building, Room 2AS.19H, 45 Center Drive MSC 6200, Bethesda, Maryland 20892-6200, or via e-mail at greenbej@gm1.nigms.nih.gov or fax at (301) 480-2228.

Individuals who plan to attend one of the regional meetings and need special assistance, such as sign language interpretation or other special accommodations, should contact the person named below in advance of the meeting.

Attendance may be limited to seat availability. If you plan to attend the meeting as an observer or if you wish additional information, please contact Ms. Janice Ramsden, National Institutes of Health, Shannon Building, Room 235, 1 Center Drive MSC 0159, Bethesda, Maryland 20892-0159, telephone (301) 496-0959, fax (301) 496-7451, e-mail address ramsdenj@aow.nih.gov by July 7 for the Bethesda meeting and August 11 for the San Francisco meeting.

Dated: June 22, 1995.

Ruth L. Kirschstein,

Deputy Director, National Institutes of Health.

[FR Doc. 95-16234 Filed 6-30-95; 8:45 am]

BILLING CODE 4140-01-P

National Institute on Deafness and Other Communication Disorders; Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

Name of Committee: Ad Hoc Hearing and Hearing Impairment Subcommittee of the National Deafness and Other Communication Disorders Advisory Council.

Date: July 20, 1995.

Time: 1-4 p.m. (telephone conference).

Place: National Institutes of Health, Building, 31C, Conference Room 9, 9000 Rockville Pike, Bethesda, Maryland 20892.

Contact Person: Mr. Baldwin Wong, Program Analyst, NIDCD/PPHRB, 31 Center Drive, MSC 2320, Room 3C-35, Bethesda, Maryland 20892-2320, (301) 496-7243.

Purpose: To recommend individuals to serve on a scientific panel to update the hearing and hearing impairment section of the Research Plan.

The meeting will be closed in accordance with the provisions set forth in sec. 552b)(c)(6), Title 5, U.S.C. These discussions could reveal personal information concerning these individuals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program No. 93.173, Biological Research Related to Deafness and Communication Disorders)

Dated: June 26, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95-16231 Filed 6-30-95; 8:45 am]

BILLING CODE 4140-01-M

Division of Research Grants; Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

Purpose/Agenda: To review individual grant applications.

Name of SEP: Behavioral and Neurosciences.

Date: July 13, 1995.

Time: 12:00 noon.

Place: Embassy Suites Hotel, Washington, DC.

Contact Person: Dr. Anita Sostek, Scientific Review Administrator, 6701 Rockledge Drive, Room 5202, Bethesda, MD 20892, (301) 435-1260.

Name of SEP: Multidisciplinary Sciences.

Date: July 14, 1995.

Time: 1:00 p.m.

Place: NIH, Rockledge II, Room 5210, Telephone Conference.

Contact Person: Dr. Nadarajen Vydelingum, Scientific Review Admin. 6701 Rockledge Drive, Room 5210, Bethesda, MD 20892, (301) 435-1176.

Name of SEP: Microbiological and Immunological Sciences.

Date: July 17, 1995.

Time: 1:00 p.m.

Place: NIH, Rockledge II, Room 4200, Telephone Conference.

Contact Person: Dr. Gil Meir, Scientific Review Administrator, 6701 Rockledge Drive, Room 4200, Bethesda, MD 20897, (301) 435-1219.

Name of SEP: Microbiological and Immunological Sciences.

Date: July 18, 1995.

Time: 10:00 a.m.

Place: NIH, Rockledge II, Room 4180, Telephone Conference.

Contact Person: Dr. Tim Henry, Scientific Review Administrator, 6701 Rockledge Drive,

Room 4180, Bethesda, MD 20892, (301) 435-1147.

Name of SEP: Microbiological and Immunological Sciences.

Date: July 18, 1995.

Time: 2:00 p.m.

Place: NIH, Rockledge II, Room 4180, Telephone Conference.

Contact Person: Dr. Tim Henry, Scientific Review Administrator, 6701 Rockledge Drive, Room 4180, Bethesda, MD 20892, (301) 435-1147.

Name of SEP: Microbiological and Immunological Sciences.

Date: July 19, 1995.

Time: 10:00 a.m.

Place: NIH, Rockledge II, Room 4180, Telephone Conference.

Contact Person: Dr. Tim Henry, Scientific Review Administrator, 6701 Rockledge Drive, Room 4180, Bethesda, MD 20892, (301) 435-1147.

Name of SEP: Microbiological and Immunological Sciences.

Date: July 19, 1995.

Time: 2:00 p.m.

Place: NIH, Rockledge II, Room 4180, Telephone Conference.

Contact Person: Dr. Tim Henry, Scientific Review Administrator, 6701 Rockledge Drive, Room 4180, Bethesda, MD 20892, (301) 435-1147.

Name of SEP: Clinical Sciences.

Date: October 2-3, 1995.

Time: 8:30 a.m.

Place: Holiday Inn, Bethesda, MD.

Contact Person: Dr. Gertrude McFarland, Scientific Review Admin., 6701 Rockledge Drive, Room 4110, Bethesda, MD 20892, (301) 435-1284.

Purpose/Agenda: To review Small Business Innovation Research Program grant applications.

Name of SEP: Multidisciplinary Sciences.

Date: July 24-25, 1995.

Time: 8:30 a.m.

Place: Holiday Inn, Chevy Chase, MD.

Contact Person: Dr. Anthony Carter, Scientific Review Admin., 6701 Rockledge Drive, Room 5108, Bethesda, MD 20892, (301) 435-1167.

Name of SEP: Clinical Sciences.

Date: December 11-12, 1995.

Time: 8:30 a.m.

Place: Holiday Inn, Bethesda, MD.

Contact Person: Dr. Gertrude McFarland, Scientific Review Admin., 6701 Rockledge

Drive, Room 4110, Bethesda, MD 20892, (301) 435-1284.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the grant review cycle.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: June 26, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95-16232 Filed 6-30-95; 8:45 am]

BILLING CODE 4140-01-M

Public Health Service

National Toxicology Program (NTP) Board of Scientific Counselors' Meetings; Announcement of NTP Draft Technical Reports Projected for Public Review From June 1995 Through Summer 1998

To earlier inform the public and allow interested parties to comment or obtain information on long-term toxicology and carcinogenesis studies prior to public peer review, the National Toxicology Program (NTP) again publishes in the **Federal Register** a current listing of draft Technical Reports projected for evaluation by the NTP Board of Scientific Counselors' Technical Reports Review Subcommittee during their next seven meetings from June 1995 through the summer of 1998. We plan to continue updating the listing with announcements in the **Federal Register** once or twice a year. The next meeting

dates are June 20-21 and December 5-6, 1995. Specific dates for 1996, 1997, and 1998 meetings will be established at a later time.

The attached Table 1 lists draft Technical Reports for long-term studies on chemicals within known or approximate dates of reviews and includes Chemical Abstracts Service (CAS) registry numbers, primary use, route of administration, species, exposure levels, and NTP report numbers (if assigned).

Technical Reports of short-term toxicity studies are currently reviewed by mail; however, they may be reviewed in open meetings when necessary. The attached Table 2 lists the draft Technical Reports of short-term toxicity studies tentatively projected for review by mail from May 1995 to October 1998 and also includes Chemical Abstracts Service (CAS) registry numbers, primary use, route of administration, species, exposure levels, and NTP report numbers (if assigned).

Those interested in having more information about any of the studies listed in this announcement should contact Central Data Management as early as possible by telephone or by mail at: MD-A0-01, NIEHS, P.O. Box 12233, Research Triangle Park (RTP), North Carolina 27709 (919/541-3419). The program would welcome receiving toxicology and carcinogenesis data from completed, ongoing or planned studies by others as well as current production data, human exposure information, and use and use patterns.

The Executive Secretary, Dr. Larry G. Hart, P.O. Box 12233, Research Triangle Park, North Carolina 27709, telephone 919/541-3971, FAX 919/541-0719 will furnish final agendas and other program information prior to a meeting, and summary minutes subsequent to a meeting.

Dated: June 16, 1995.

Kenneth Olden,

Director, National Toxicology Program.

TABLE 1.—SUMMARY DATA FOR TECHNICAL REPORTS SCHEDULED FOR REVIEW AT THE MEETING OF THE NTP BOARD OF SCIENTIFIC COUNSELORS' TECHNICAL REPORTS REVIEW SUBCOMMITTEE FROM JUNE 20, 1995 THROUGH SUMMER 1998

Chemical name/cas No.	Use	Route	Species	Exposure levels	NTP Tr No.
Chemicals Tentatively Scheduled for Peer Review June 20-21, 1995					
BUTYL BENZYL PHTHALATE; 85-68-7	PLAS	FEED	RR	MR: 0, .3%, .6%, OR 1.2%; 60/GROUP FR: 0, .6%, 1.2%, OR 2.4%; 60/GROUP.	458
T-BUTYLHYDROQUINONE; 1948-33-0	FOOD	FEED	RMR	R&M: 0, 0.125, 0.25, OR 0.5% IN FEED; 70 RATS, 60 MICE.	459
CODEINE; 76-57-3	PHAR	FEED	RM	R: 0, 400, 800, OR 1600 M: 0, 750, 1500, OR 3000 PPM; 60/GROUP.	455